Literature DB >> 20974617

Evidence of a non-progressive course of alternating hemiplegia of childhood: study of a large cohort of children and adults.

Eleni Panagiotakaki1, Giuseppe Gobbi, Brian Neville, Friedrich Ebinger, Jaume Campistol, Sona Nevsímalová, Laura Laan, Paul Casaer, Georg Spiel, Melania Giannotta, Carmen Fons, Miriam Ninan, Guenter Sange, Tsveta Schyns, Rosaria Vavassori, Dominique Poncelin, Alexis Arzimanoglou.   

Abstract

Alternating hemiplegia of childhood is a neurological disorder characterized by episodes of hemiplegia, various non-epileptic paroxysmal events and global neurological impairment. Characterization of the evolution and outcome into adulthood has not been sufficiently investigated. The goal of this study was to elucidate the natural history of alternating hemiplegia within a large cohort of 157 patients, as part of the European Network for Research on Alternating Hemiplegia project. A questionnaire was formulated to determine the severity of both paroxysmal and global neurological impairment and address progression of the disorder by allocating data to specific age epochs up to and over 24 years of age. Patients in early age groups were consistently present in subsequent later age groups and for each patient, data were collected for each corresponding age epoch. The study was based on predominantly retrospective and, for a period of 2 years, prospective data. At inclusion, patients were aged from 9 months to 52 years. The median age at diagnosis was 20 months. All patients experienced hemiplegic attacks; 86.5% reported episodes of bilateral weakness, 88% dystonic attacks, 53% epileptic seizures, 72% developed chorea and/or dystonia and 92% mental retardation. When data over the course of the illness were examined for the whole cohort, the severity of symptoms did not appear to change, with the exception of abnormal ocular movements and hypotonia that regressed, but did not disappear into adulthood (from 86 to 36% and 76 to 36%, respectively). No statistically significant correlation between a history of severe paroxysmal hemiplegic/dystonic episodes and a worse neurological outcome was identified. Seven patients died, some of whom experienced severe plegic attacks or epileptic seizures at the time of death. History of severe plegic/dystonic attacks was not found to be an aggravating factor for deceased patients. Our results provide evidence that the natural history of alternating hemiplegia is highly variable and unpredictable for individual patients. However, we did not find evidence to support a steadily progressive and degenerative course of the disorder when patients were analysed as a group. For a minority of patients, a risk of sudden death was associated with more severe neurological impairment. The European Network for Research on Alternating Hemiplegia Registry, validated by our study, includes all major neurological signs and symptoms of alternating hemiplegia and may thus be used as a precedent for the progressive inclusion and follow-up of patients as well as a reference for genetic studies and treatment trials.

Entities:  

Mesh:

Year:  2010        PMID: 20974617     DOI: 10.1093/brain/awq295

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  43 in total

1.  Polysomnography Findings and Sleep Disorders in Children With Alternating Hemiplegia of Childhood.

Authors:  Sujay Kansagra; Ryan Ghusayni; Bassil Kherallah; Talha Gunduz; Melissa McLean; Lyndsey Prange; Richard M Kravitz; Mohamad A Mikati
Journal:  J Clin Sleep Med       Date:  2019-01-15       Impact factor: 4.062

Review 2.  Pediatric migraine variants: a review of epidemiology, diagnosis, treatment, and outcome.

Authors:  Ana Marissa Lagman-Bartolome; Christine Lay
Journal:  Curr Neurol Neurosci Rep       Date:  2015-06       Impact factor: 5.081

Review 3.  ICHD-3: what changes do we need regarding migraine?

Authors:  Gian Camillo Manzoni; Ilaria Grisendi; Paola Torelli
Journal:  Curr Pain Headache Rep       Date:  2011-06

4.  Topiramate Therapy in Alternating Hemiplegia of Childhood.

Authors:  Ananthanarayanan Kasinathan; Indar Kumar Sharawat; Jitendra Kumar Sahu; Naveen Sankhyan
Journal:  Indian J Pediatr       Date:  2017-05-13       Impact factor: 1.967

5.  Mosaicism in ATP1A3-related disorders: not just a theoretical risk.

Authors:  Marie Hully; Juliette Ropars; Laurence Hubert; Nathalie Boddaert; Marlene Rio; Mathieu Bernardelli; Isabelle Desguerre; Valerie Cormier-Daire; Arnold Munnich; Pascale de Lonlay; Louise Reilly; Claude Besmond; Nadia Bahi-Buisson
Journal:  Neurogenetics       Date:  2016-10-10       Impact factor: 2.660

6.  White matter and cerebellar involvement in alternating hemiplegia of childhood.

Authors:  Mariasavina Severino; Livia Pisciotta; Domenico Tortora; Benedetta Toselli; Michela Stagnaro; Ramona Cordani; Giovanni Morana; Anna Zicca; Svetlana Kotzeva; Clelia Zanaboni; Giovanni Montobbio; Andrea Rossi; Elisa De Grandis
Journal:  J Neurol       Date:  2020-01-16       Impact factor: 4.849

7.  No Mutation in the SLC2A3 Gene in Cohorts of GLUT1 Deficiency Syndrome-Like Patients Negative for SLC2A1 and in Patients with AHC Negative for ATP1A3.

Authors:  C Le Bizec; S Nicole; E Panagiotakaki; N Seta; S Vuillaumier-Barrot
Journal:  JIMD Rep       Date:  2013-09-04

8.  A Transgenic Mouse Model to Selectively Identify α3 Na,K-ATPase Expressing Cells in the Nervous System.

Authors:  Maxim Dobretsov; Abdallah Hayar; Neriman T Kockara; Maxim Kozhemyakin; Kim E Light; Pankaj Patyal; Dwight R Pierce; Patricia A Wight
Journal:  Neuroscience       Date:  2018-07-19       Impact factor: 3.590

9.  Cognitive impairment in rapid-onset dystonia-parkinsonism.

Authors:  Jared F Cook; Deborah F Hill; Beverly M Snively; Niki Boggs; Cynthia K Suerken; Ihtsham Haq; Mark Stacy; W Vaughn McCall; Laurie J Ozelius; Kathleen J Sweadner; Allison Brashear
Journal:  Mov Disord       Date:  2014-01-16       Impact factor: 10.338

Review 10.  Episodic movement disorders: from phenotype to genotype and back.

Authors:  Knut Brockmann
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.